Decision Timeline: Considerations in Selecting an Outsourced Solution

Continuous or Batch: Deciding on the Best Solution for your Oral Solid Dose Product

Continuous manufacturing enables the development of a more diverse pipeline of drug products by greater quality assurance, reduced API usage, and timeline efficiencies. It also reduces scaleup activities as a product increases in volume in the clinical phase through commercial. With that comes the benefits of reduced API usage, and therefore costs. Additional benefits include timeline efficiencies as well as a reduction of technical risks, as continuous manufacturing systems are designed with integrated solutions that allow for real-time analysis and control.

Telltale Signs You’re with the Wrong CDMO

Late-stage drug development efforts have many moving parts as projects push toward commercialization. During this critical time, companies often take a good long look at their vendors and evaluate their options for scale up to commercial launch. Is your CDMO an asset or a hindrance in this process? How can you recognize whether your partners really contribute everything they can to your end goal of commercialization?

Continuous manufacturing: The alternative to batch manufacturing

The pharmaceutical industry is facing increasing pressures on quality, pricing and productivity. The traditional batch method of manufacturing oral solid dose medications has limited scope to address these needs. Thermo Fisher Scientific offers a new alternative to batch manufacturing. Continuous manufacturing can deliver higher quality oral solid dose products, with greater flexibility and a reduced total cost of supply.

How Pacira Pharma Is Working To Help Curb The Opioid Epidemic

Poorly managed postoperative pain can have a significant impact on a patient’s recovery. Consequently, more patients relying in opioids furthers compounds the opioid epidemic. This case study discusses how Patheon and Pacira Pharma partnered to help curb this epidemic.

Collegium Pharmaceutical’s Approach to Abuse Deterrence Breaks New Ground

The opioid abuse epidemic is a serious public health crisis that demands action on the part of many stakeholders. While abuse-deterrent opioids will not solve the opioid abuse epidemic alone, they play a critical role in the fight against it. While Collegium had come up with an innovative new approach to abuse deterrent formulations, it did not have the capacity or resources to manufacture its drug on a commercial scale.

Fighting The Opioid Epidemic: How Grünenthal’s Abuse-Deterrent Technology Contributes

As part of the FDA’s efforts to address opioid addiction, the agency put an opioid action plan into effect in 2011 to “reduce opioid abuse, dependence, and overdose in the United States.” Part of this plan included a call to pharmaceutical manufacturers to develop and expand access to abuse-deterrent formulations (ADFs) in order to discourage abuse among patients and promote innovation in the industry.

Biologics & Flexible Biomanufacturing Overview Brochure

Your molecule has the power to change lives and shape the future. Patheon is the company that offers you the agility and speed to help you get there ahead of schedule while maintaining the highest quality. We bring deep scientific expertise to every challenge and our proven track record of scaling up biologics help ensure you gain cost and time savings at every stage of the biologic development process.

Technology Transfers: Reaping Rewards, Reducing Risks

In 2016, Patheon successfully completed 111 technology transfers to help our clients safeguard supply, improve distribution and reduce program costs and risks. This has allowed firms to take advantage of specialist expertise, solid processes and standardized operating procedures and equipment.

Solving the OOS Problem with Continuous Manufacturing

The goal of Pharmaceutical Process design has long been to implement a fixed process that can produce on-spec materials, which can be confirmed by quality testing.

Impact of Incorrect Forecasts on New Product Launches

Pharmaceutical companies around the world are under tremendous pressure – from regulators, legislators, payers, and patients – to reduce the cost of drugs. In response to the outcry for cost-cutting, pharmaceutical company leaders are examining every aspect of their business to determine where they can derive savings, particularly when planning for the launch of a new product.

Built To Fail: How Today’s Manufacturing Options Leave Pharma At Risk

When planning for the commercialization of a new product, pharmaceutical manufacturing executives must plan for capacity needs very early in the process. Download this whitepaper to learn about key variables that manufacturing executives should consider when evaluating flexible manufacturing solutions for commercial manufacturing projects.